Updates are available Correction dated 2021-11-02
Click to view Correction: https://doi.org/10.1007/s00198-021-06156-2
-
Authors
Deminger, A. http://orcid.org/0000-0001-6423-1623
Klingberg, E.
Lorentzon, M.
Hedberg, M.
Carlsten, H.
Jacobsson, L.T.H.
Forsblad-d’Elia, H.
-
Funding
Funding for this research was provided by:
Västra Götalandsregionen (VGFOUREG-383071, VGFOUREG-564511, VGFOUREG-754661)
Vetenskapsrådet (2016-02035, 2017-02229)
The Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALFGBG-141111, ALFGBG-430851, , ALFVLL-640251, ALFGBG-716051)
Svenska Läkaresällskapet
Göteborgs Läkaresällskap (GLS-880811, GLS-498111, GLS-406801)
Reumatikerförbundet
Reumatikerdistriktet i Göteborg
Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning
IngaBritt och Arne Lundbergs Forskningsstiftelse
Controlling Chronic Inflammatory Diseases with Combined Efforts
Stiftelsen Reuma Forskningsfond Margareta
Open access funding provided by University of Gothenburg
- License Information
-
More Information
Article History
Received: 19 October 2020
Accepted: 24 June 2021
First Online: 14 July 2021
Change Date: 2 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00198-021-06156-2
Declarations
:
: All procedures performed in the study involving human participants were in accordance with the ethical standards of the regional ethics committee in Gothenburg, Sweden (reference numbers Dnr: 597-08 and Dnr: 690-13) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: EK has received Advisory Board Fees from Novartis, lecturing fees from Lilly, and an unrestricted grant from Roche, outside the submitted work. ML has received lecturing fees from Amgen, Meda, Jansen-Cilag AB, Consilient Health, and Lilly, consulting fees from Radius Health and UCB Pharma, and a grant from BioGaia AB, outside the submitted work. LTHJ has received Advisory Board Fees from Novartis, Celgene, and Eli Lilly, outside the submitted work. HFd’E has received Advisory Board Fees from Sandoz, AbbVie, and Novartis and an unrestricted grant from Novartis, outside the submitted work. AD, MH, and HC report no competing interests.
: Not applicable.
